Marc Tessier-Lavigne
Biotech

Buzzy AI biotech Xaira unveils antibody platform ambitions

CEO Marc Tessier-Lavigne, Ph.D., told Fierce of Xaira's “major focus to develop a model that can design antibodies that are drug-ready from the start”
Darren Incorvaia Oct 2, 2026 11:00am
NVS

Novartis pens $7.8B deal for Abogen's in vivo autoimmune TCE

Oct 2, 2026 4:24am
New approach methodologies in safety and toxicology testing Why proving repeatability is the next hurdle for widespread adop

NAMs: Why proving repeatability is the next hurdle for widespread adoption

Brought to you by Agilent Technologies
closed shuttered shut down closed

Adecto blames ‘risk-adverse funding environment’ for closing

Oct 2, 2026 3:53am
Ashley Magargee

Genentech's CEO on the next 50 years of the original biotech

Oct 1, 2026 8:00am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

Bayer taps new chief medical officer—Chutes & Ladders

Oct 2, 2026 8:30am
More News

Fierce Biotech Layoff Tracker 2026: Foghorn, BioMarin & more

Oct 1, 2026 10:30am

Analysts unshaken by patient death in BMS lung fibrosis trial

Oct 1, 2026 10:22am

Recruiters see ‘signs of recovery’ as biotech layoffs stay cool

Oct 1, 2026 9:00am

Foghorn lays off 40% of employees as Lilly collab collapses

Oct 1, 2026 8:36am